RayKnowChina Research Map
Shortlist0

Enrolling by invitationHepatocellular carcinomaPhase 1

Registered title, quoted from ClinicalTrials.gov

JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Xiangya Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorXiangya Hospital中南大学湘雅医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06882876, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or pathologically confirmed unresectable hepatocellular carcinoma;

    Inclusion criterion 2

  3. Child-Pugh score of ≤7;

    Inclusion criterion 5

    BCLC/B stage; not previously treated with anti-cancer therapy; at least one measurable lesion (according to RECIST 1.1 criteria).

    Inclusion criterion 6

  4. Within 28 days prior to the start of the study, the participant received treatment with another investigational drug or participated in another clinical study for a different therapeutic indication.;

    Exclusion criterion 2

  5. Eastern Cooperative Oncology Group (ECOG) PS score of 0-1;

    Inclusion criterion 4

  6. Pregnant or breastfeeding women;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06882876, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Sign the informed consent form, voluntarily participate in this study, good compliance and follow-up cooperation.
  • Histologically or pathologically confirmed unresectable hepatocellular carcinoma;
  • Male or female patients aged 18-75 years;
  • Eastern Cooperative Oncology Group (ECOG) PS score of 0-1;
  • Child-Pugh score of ≤7;
  • BCLC/B stage; not previously treated with anti-cancer therapy; at least one measurable lesion (according to RECIST 1.1 criteria).
  • Sufficient organ function in vital organs (excluding serious functional impairment in the heart, lung, liver, kidney, bone marrow, nervous system, and endocrine systems).

Exclusion Criteria:

  • Diagnosed with fibrolamellar carci-noma of liver, intrahepatic cholangiocarcinoma, and mixed carcinoma;
  • Within 28 days prior to the start of the study, the participant received treatment with another investigational drug or participated in another clinical study for a different therapeutic indication.;
  • Based on the investigator's judgment, the patient is expected to live for less than 12 weeks;
  • Uncontrolled pleural effusion, pericardial effusion, or ascites of moderate volume or more;
  • Current or past history of central nervous system metastasis;
  • Have a history of psychotropic drug abuse or drug use;
  • Hereditary or acquired tendency towards bleeding and thrombosis, a thromboembolic event occurred within the past 6 months;
  • Have a history of severe allergy to any monoclonal antibody, Toripalimab , JS014 and other ingredients of this study;
  • Pregnant or breastfeeding women;
  • Subjects with other factors that, in the judgment of the investigator, may cause the study to be prematurely terminated.

Quoted from ClinicalTrials.gov, NCT06882876, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06882876, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06882876